Medpace Holdings, Inc. (MEDP)

NMS – Real Time Price. Currency in USD

451.20

-15.40 (-3.30%)

At close: Mar 27, 2026, 4:00 PM EDT

451.79

+0.59 (0.13%)

After-hours: Mar 27, 2026, 7:38 PM EDT

25.03.2026

Why Medpace (MEDP) Outpaced the Stock Market Today

In the closing of the recent trading day, Medpace (MEDP) stood at $466.8, denoting a +1.32% move from the preceding trading day.

24.03.2026

Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you jo.

23.03.2026

PACS or MEDP: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical Services stocks have likely encountered both PACS Group, Inc. (PACS) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?

19.03.2026

Why the Market Dipped But Medpace (MEDP) Gained Today

In the closing of the recent trading day, Medpace (MEDP) stood at $460.92, denoting a +1.35% move from the preceding trading day.

05.03.2026

PACS vs. MEDP: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical Services sector have probably already heard of PACS Group, Inc. (PACS) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?

27.02.2026

Medpace (MEDP) Rises As Market Takes a Dip: Key Facts

Medpace (MEDP) reached $447.09 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.

23.02.2026

Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates

New York, New York--(Newsfile Corp. - February 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ: MEDP) concerning potential violations of the federal securities laws. On February 10, 2026, Medpace shares fell approximately 10% by mid-day and closed down 15.9%, according to data from Quiver Quantitative and GuruFocus.

Videos

No Data

There is no data to display

Press releases

23.02.2026

Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates

18.02.2026

Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility

(NASDAQ: MEDP) NEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential securities law claims on behalf of shareholders. The investigation centers on whether the company and its senior officers made statements about the health of its clinical-trial booking pipeline that were inconsistent with internal data showing elevated cancellation rates and a deteriorating book-to-bill ratio.

17.02.2026

Lost Investment in Medpace Holdings, Inc. (MEDP)? Levi & Korsinsky Launches Securities Fraud Investigation

New York, New York--(Newsfile Corp. - February 17, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Medpace Holdings, Inc. ("Medpace Holdings, Inc.") (NASDAQ: MEDP) concerning potential violations of the federal securities laws. On February 10, 2026, Medpace shares fell approximately 10% by mid-day and closed down 15.9%, according to data from Quiver Quantitative and GuruFocus.

11.02.2026

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Oslo, Norway – 11 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a clinical partnership with Medpace, a leading global Contract Research Organization (CRO), to support the first clinical trial of ZI-MA4-1 (ZIMA-101), Zelluna's lead product candidate.

Medpace Holdings, Inc. (MEDP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Medpace Holdings, Inc. (MEDP)

Why Medpace (MEDP) Outpaced the Stock Market Today

Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

PACS or MEDP: Which Is the Better Value Stock Right Now?

Why the Market Dipped But Medpace (MEDP) Gained Today

PACS vs. MEDP: Which Stock Is the Better Value Option?

Medpace (MEDP) Rises As Market Takes a Dip: Key Facts

Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates

Videos

No Data

Press releases

Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates

Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility

Lost Investment in Medpace Holdings, Inc. (MEDP)? Levi & Korsinsky Launches Securities Fraud Investigation

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Why Medpace (MEDP) Outpaced the Stock Market Today

Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

PACS or MEDP: Which Is the Better Value Stock Right Now?

Why the Market Dipped But Medpace (MEDP) Gained Today

PACS vs. MEDP: Which Stock Is the Better Value Option?

Medpace (MEDP) Rises As Market Takes a Dip: Key Facts

Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates

Videos

No Data

Press releases

Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates

Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility

Lost Investment in Medpace Holdings, Inc. (MEDP)? Levi & Korsinsky Launches Securities Fraud Investigation

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial